Can Hyperparathyroidism Cause Kidney Disease?

Hyperparathyroidism can cause kidney disease through several distinct pathways, including kidney stones, calcium deposits in kidney tissue, impaired ability to concentrate urine, and gradual loss of filtering capacity. The relationship between the parathyroid glands and the kidneys runs in both directions, though. While overactive parathyroid glands can damage the kidneys, existing kidney disease is itself one of the most common reasons parathyroid glands become overactive in the first place. Untangling which direction the damage is flowing, and how aggressively to treat it, turns out to be more complicated than the simple question suggests.

How Excess Parathyroid Hormone Harms the Kidneys

Parathyroid hormone (PTH) regulates calcium levels in the blood, pulling calcium from bones, boosting calcium absorption in the gut (via vitamin D), and telling the kidneys to hold onto calcium rather than excreting it. When the parathyroid glands produce too much PTH, blood calcium rises, and the kidneys bear much of the fallout. The damage happens through a handful of mechanisms that can operate simultaneously.

The most straightforward path is through kidney stones. Elevated calcium in the blood leads to elevated calcium in the urine, and that excess calcium can crystallize into stones. Hypercalciuria is one of several factors involved in the complex process of stone formation in primary hyperparathyroidism (PHPT), along with changes in urine pH and concentration.¹ Repeated stone episodes can scar the kidneys and obstruct urine flow, both of which chip away at long-term kidney function.

A less obvious but potentially more insidious form of damage is nephrocalcinosis, where calcium deposits form directly within the kidney tissue itself rather than crystallizing into discrete stones. This process can silently reduce how well the kidneys filter blood, sometimes before a patient has any symptoms at all.

High blood calcium also disrupts the kidney’s ability to concentrate urine. In animal models, hypercalcemia triggers a targeted breakdown of aquaporin-2, a water channel protein in the kidney’s collecting ducts. This degradation leads to a condition called nephrogenic diabetes insipidus, where the kidneys produce large volumes of dilute urine regardless of how much water you drink.² That excessive fluid loss can lead to dehydration and further stress on the kidneys.

PTH also directly affects the blood vessels inside the kidneys. In isolated kidney preparations, both PTH and a related protein dilate the tiny arteries feeding the glomeruli (the kidney’s filtering units), increasing blood flow through them. The vessels carrying blood away from the glomeruli are not similarly dilated, and PTH may even constrict them by stimulating renin release.³ Over time, this imbalance in pressure within the filtering units can contribute to structural damage.

Does Hyperparathyroidism Actually Speed Up Kidney Function Loss?

Given all those mechanisms, you might expect every person with hyperparathyroidism to show rapid kidney decline. The clinical reality is more nuanced. It depends heavily on how high the calcium goes.

A large study tracking over 43,000 patients with PHPT found that about 84 percent of them had only mildly elevated calcium, and their rate of kidney function decline was roughly the same as that of people without the condition. The kidney’s filtering rate dropped at about the same pace you would expect from aging alone. Only the roughly 16 percent of patients with significantly elevated calcium, above about 11.5 mg/dL, showed a meaningfully faster decline.⁴ Among the highest calcium group (above roughly 12 mg/dL), kidney function dropped at about twice the rate of healthy controls.

Another study examining what predicts kidney trouble in mild PHPT found that the usual suspects, like high blood pressure, diabetes, and age, mattered more than the hyperparathyroidism-specific lab values themselves.⁵ In other words, for the majority of people with mild primary hyperparathyroidism, the conventional cardiovascular and metabolic risk factors still drive kidney outcomes more than the parathyroid disease itself.

This does not mean mild hyperparathyroidism is harmless to the kidneys. Sensitive biomarkers suggest subclinical kidney injury may be occurring even when standard lab tests look normal. Patients with PHPT have higher levels of KIM-1 (a marker of tubular damage) in their urine compared to healthy controls, and this difference is most pronounced in people whose kidney filtering rates still fall within the mildly reduced range. Patients who also have kidney stones show higher levels of NGAL, another injury marker, in proportion to their calcium levels.⁶ The practical upshot: standard blood tests may underestimate how much low-grade kidney damage is accumulating in PHPT.

Kidney Stones and the Question of Surgery

Kidney stones are the most common kidney-related complication of PHPT and often the reason the condition gets diagnosed in the first place. Stones form because the kidneys are excreting too much calcium, but the calcium excess is just one piece of the puzzle. Changes in urine acidity, volume, and the concentration of other stone-inhibiting substances all play roles.¹

The hope has always been that removing the overactive parathyroid gland (parathyroidectomy) would stop the stones from coming back. A systematic review found that surgery does significantly reduce stone recurrence over the long term, but it does not eliminate the risk entirely. There is even a short-term window after surgery when stone risk may temporarily rise, likely because of shifts in calcium handling as the body adjusts.⁷ Over time, however, the recurrence rate drops substantially compared to patients who do not have surgery.

What about kidney function itself after surgery? The picture is complicated. A large study of over 43,000 PHPT patients found that overall, parathyroidectomy did not change the risk of a major decline in kidney function compared to non-surgical management. At ten years, about 11 percent of surgical patients and 12 percent of non-surgical patients had experienced a drop of at least 50 percent in their kidney filtering rate.⁸ That looks like a wash. But buried within that average is an important detail: in patients with the highest calcium levels (above about 11.5 mg/dL), surgery did slow the rate of kidney decline.⁴

A smaller prospective study found that patients who already had reduced kidney function before surgery (filtering rate below 60 mL/min) were the most likely to see improvement afterward, with nearly half of them moving up to a better stage of kidney disease. Patients who started with normal kidney function, by contrast, saw a slight decline on average.⁹ There is also a predictable short-term dip in kidney function right after surgery, as the sudden drop in PTH reduces the hyperfiltration that had been propping up the numbers. Most of that acute dip recovers within the first month, but a permanent decrease of a few percentage points is common at one year.¹⁰

So the honest summary: surgery helps the kidneys most in people whose calcium is significantly elevated or whose kidneys are already struggling. For the majority with mild disease and preserved kidney function, the kidney-specific benefit of surgery is hard to detect.

When Kidney Disease Causes Hyperparathyroidism

The question in the title runs in one direction, but the reverse direction is actually more common in clinical practice. As kidney disease progresses, the kidneys lose their ability to activate vitamin D and to excrete phosphorus efficiently. Phosphorus builds up, active vitamin D drops, and blood calcium falls. In response, the parathyroid glands ramp up PTH production. This is called secondary hyperparathyroidism, and it develops in nearly every patient with advanced chronic kidney disease.¹¹

The parathyroid glands initially enlarge evenly (diffuse hyperplasia), but over years of relentless stimulation they can develop nodules of tissue that no longer respond normally to feedback signals. At that point, the glands may start pouring out PTH regardless of the calcium level, sometimes pushing calcium dangerously high even though the kidneys are still failing. That autonomous overproduction is called tertiary hyperparathyroidism, and it represents one of the more difficult management challenges in end-stage kidney disease.¹² Tertiary hyperparathyroidism can cause abnormal bone remodeling, soft tissue calcification, and vascular damage that compounds the already heavy cardiovascular burden of kidney failure.¹³

This creates a vicious feedback loop. Kidney disease drives up PTH, and the elevated PTH then accelerates vascular calcification. In animal experiments, sustained high PTH levels caused intense calcification in the aorta and even the coronary arteries, independent of whether the animals had kidney failure.¹⁴ The calcified blood vessels become stiffer, which raises blood pressure and further damages the kidneys. One study found a positive correlation between PTH levels and the resistance of blood flow through the kidneys (measured by the renal resistive index) in PHPT patients. After parathyroidectomy, that correlation disappeared, suggesting that the elevated PTH was contributing to stiffer renal blood vessels.¹⁵

The Normocalcemic Variant

There is a form of primary hyperparathyroidism where PTH is elevated but blood calcium remains within the normal range. This normocalcemic variant accounts for a surprisingly large share of cases. Among patients being evaluated for kidney stones who turn out to have PHPT, roughly 40 percent may have the normocalcemic form when tested carefully with ionized calcium measurements after a calcium load.¹⁶

Whether normocalcemic PHPT causes the same kidney complications as the classic hypercalcemic form is still being worked out. These patients do form kidney stones, but a case report found that even after surgical removal of a parathyroid adenoma, kidney stone risk did not improve based on urine chemistry and imaging follow-up.¹⁷ One especially interesting finding is that after a calcium load, patients with normocalcemic PHPT dumped proportionally more calcium into their urine than patients with the classic hypercalcemic form, with a renal calcium excretion increase of about 300 percent versus 176 percent.¹⁶ That exaggerated calcium spill may explain why these patients form stones despite having “normal” calcium on routine blood work.

Medical Management with Calcimimetics

Not everyone with hyperparathyroidism is a candidate for surgery. Calcimimetics, drugs that trick the parathyroid glands into sensing more calcium than is actually present, offer an alternative. Cinacalcet is the most widely used. In hemodialysis patients with secondary hyperparathyroidism, cinacalcet cut PTH levels by about 43 percent on average, compared to a 9 percent rise in the placebo group, and the calcium-phosphorus product (a measure linked to calcification risk) dropped by 15 percent.¹⁸

In patients with varying degrees of kidney impairment, cinacalcet lowered calcium and PTH levels, but kidney function itself did not change significantly.¹⁹ In kidney transplant recipients with persistent hyperparathyroidism, the drug brought calcium back to normal and gradually lowered PTH, but kidney filtering rate actually dipped slightly at every follow-up point.²⁰ The eGFR decline in that setting may reflect the same phenomenon seen after surgery: remove the PTH-driven hyperfiltration, and the measured kidney function drops, even though the underlying kidney tissue may actually be under less stress.

A meta-analysis of randomized trials in PHPT confirmed that cinacalcet probably reduces serum calcium and PTH, while other medical therapies like alendronate, denosumab, vitamin D, and estrogen primarily improve bone density without consistently lowering calcium or PTH.²¹ Vitamin D supplementation, incidentally, does not appear to worsen hypercalcemia in PHPT patients who are also vitamin D deficient, which is reassuring since many clinicians hesitate to prescribe it in that setting.²²

Lithium and Hyperparathyroidism

Lithium, a mainstay of bipolar disorder treatment, can cause hyperparathyroidism on its own, and it also independently damages the kidneys. A cohort study of patients on long-term lithium therapy found that kidney function deteriorated by about 2.9 mL/min per year, and the duration of lithium use correlated with both the development of hyperparathyroidism and rising calcium levels.²³ This creates a double hit: lithium directly impairs kidney concentrating ability and filtering capacity, while the hyperparathyroidism it triggers adds calcium-mediated damage on top. Patients on lithium for many years need monitoring of both kidney function and parathyroid hormone, because the two problems can compound each other in ways that are easy to miss if you only track one.

Hyperparathyroidism and Kidney Stones During Pregnancy

Primary hyperparathyroidism during pregnancy is uncommon but deserves mention because the stakes are higher. Calcium demands rise during pregnancy, and PHPT can push blood calcium to levels that cause kidney stones along with serious maternal and fetal complications.²⁴ Kidney stones during pregnancy are harder to diagnose (imaging options are limited) and harder to treat (some interventions carry fetal risk). When PHPT is the underlying cause, the management decision often involves weighing the risks of surgery during pregnancy against the risks of continued hypercalcemia. There is no one-size-fits-all answer, but awareness that hyperparathyroidism can be driving recurrent stones in a pregnant patient matters, because the treatment is fundamentally different from managing an ordinary stone.

Who Needs Monitoring Versus Immediate Treatment

Primary hyperparathyroidism has shifted dramatically over the past several decades from a disease diagnosed through severe kidney and bone complications to one caught incidentally on routine blood work when calcium comes back slightly high. Most patients today are considered “asymptomatic,” though as the biomarker research mentioned earlier suggests, truly asymptomatic may be overstating matters.

The data on kidney outcomes suggest a practical dividing line. Patients whose calcium sits only mildly above normal, roughly below 11.5 mg/dL, lose kidney function at about the same rate as the general population, and surgery does not appear to change that trajectory in any measurable way.⁸ Those patients can often be monitored with periodic calcium, PTH, and kidney function checks. The patients who benefit most from surgery, at least from a kidney perspective, are those with clearly elevated calcium above that threshold or those whose kidney function is already reduced below about 60 mL/min.⁹ A history of kidney stones also tips the balance toward surgery, since parathyroidectomy reduces long-term stone recurrence even if it does not eliminate it completely.⁷

If you have been told your parathyroid hormone is elevated, the kidney question worth asking your doctor is not just “what is my creatinine?” but also whether a 24-hour urine collection for calcium, a look at stone risk factors, and possibly sensitive tubular injury markers might reveal damage that standard blood tests miss. The kidneys are remarkably good at compensating until they are not, and the gap between “labs look fine” and “subclinical injury is accumulating” is exactly where primary hyperparathyroidism likes to hide.

1
PubMed Central. Renal manifestations of primary hyperparathyroidism
2
PubMed. Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus
3
PubMed Central. Vascular effects of parathyroid hormone and parathyroid hormone-related protein in the split hydronephrotic rat kidney
4
European Journal of Endocrinology. Long-term effects of primary hyperparathyroidism and parathyroidectomy on kidney function
5
The Journal of Clinical Endocrinology & Metabolism. Predictors of Renal Function in Primary Hyperparathyroidism
6
PubMed. Investigating subtle kidney injury in primary hyperparathyroidism by means of sensitive and specific biomarkers
7
PubMed Central. Effect of parathyroidectomy on stone recurrence in primary hyperparathyroidism: A systematic review
8
PubMed Central. Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism
9
PubMed. Effects of parathyroidectomy on kidney function in patients with primary hyperparathyroidism: Results of a prospective study
10
PLoS ONE. Acute and long-term kidney function after parathyroidectomy for primary hyperparathyroidism
11
PubMed Central. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
12
PubMed Central. Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
13
New Emirates Medical Journal. Tertiary Hyperparathyroidism and Extra Skeletal Calcification in End Stage Kidney Disease Patients: Case-series and Literature Review
14
PubMed. Vascular calcification: contribution of parathyroid hormone in renal failure
15
The Journal of Clinical Endocrinology & Metabolism. Impact of Parathyroidectomy on Vascular Stiffness: Exploring Pulse Wave Velocity and Renal Resistive Index
16
PubMed Central. Comparison of Normocalcemic vs Hypercalcemic Primary Hyperparathyroidism in a Hypercalciuric Renal Stone Population
17
PubMed Central. Kidney Stone Risk in Normocalcemic Hyperparathyroidism before and after Parathyroid Surgery
18
PubMed. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
19
PubMed. Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure
20
Transplantation. The Effect of Cinacalcet on Bone Remodeling and Renal Function in Transplant Patients With Persistent Hyperparathyroidism
21
PubMed. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
22
PubMed. Safety of vitamin D replacement in patients with primary hyperparathyroidism and concomitant vitamin D deficiency
23
PubMed Central. Long-term lithium therapy and risk of chronic kidney disease, hyperparathyroidism and hypercalcemia: a cohort study
24
Urology. Nephrolithiasis during pregnancy secondary to primary hyperparathyroidism